Related Experiment Videos
Preliminary efficacy of levetiracetam in children
Tracy A Glauser1, Olivier Dulac
1Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, United States. glauser@chmcc.org
Insights
Levetiracetam effectively reduces seizure frequency in pediatric patients. This antiepileptic drug demonstrates a favorable safety profile in children, similar to adults, with manageable pharmacokinetic differences.
Area of Science:
- Pediatric Neurology
- Pharmacology
- Clinical Trials
Background:
- Treatment of pediatric seizures presents unique challenges due to differing disease etiology and drug pharmacokinetics compared to adults.
- Limited controlled clinical trials in children necessitate reliance on smaller studies or extrapolation from adult data for antiepileptic drug (AED) selection.
- Understanding AED efficacy and safety in pediatric populations is crucial for effective seizure management.
Purpose of the Study:
- To evaluate the efficacy and safety of levetiracetam in treating seizure disorders in pediatric patients.
- To assess the pharmacokinetic profile and tolerability of levetiracetam in children.
- To provide evidence-based guidance for the use of levetiracetam in pediatric epilepsy management.
Main Methods:
- Analysis of data from numerous children with diverse seizure disorders, including prospective studies and retrospective evaluations.
- Assessment of seizure frequency reduction and adverse event profiles.
- Evaluation of pharmacokinetic parameters, including metabolism and clearance rates in pediatric subjects.
Main Results:
- Levetiracetam demonstrated a reduction in seizure frequency across a wide range of pediatric seizure disorders.
- The drug was generally well-tolerated in pediatric patients, exhibiting a safety profile comparable to adults.
- No idiosyncratic adverse reactions were reported, and behavioral disturbances were infrequent.
Conclusions:
- Levetiracetam is an effective and well-tolerated option for managing seizures in pediatric patients.
- Pediatric patients exhibit faster metabolism and clearance of levetiracetam, necessitating weight-based dose adjustments.
- Ongoing studies will further elucidate the pharmacokinetics, efficacy, and safety of levetiracetam in this population.
Abstract:
Treatment of seizures in pediatric patients is complicated by the fact that the etiology of the disorder and the pharmacokinetics, efficacy, and safety of antiepileptic drugs (AEDs) may differ from that in adults. With few controlled clinical trials of AEDs in children, the selection of agents to treat pediatric patients must be made on the basis of information from small uncontrolled studies or the extrapolation of clinical trial results in adults. Data from a large number of children with a wide range of seizure disorders who were treated in small-scale prospective studies, or whose records were retrospectively evaluated, indicate that levetiracetam reduces the frequency of seizures in pediatric patients. Available data also indicate that levetiracetam is well tolerated in pediatric patients, with a safety profile similar to that in adults, a low potential for behavioral disturbances, and no reported idiosyncratic adverse reactions. As with other AEDs, children metabolize and clear levetiracetam more rapidly than adults, and somewhat higher doses (based on body weight) are needed to achieve desired plasma concentrations. Several ongoing studies will provide further information on the pharmacokinetics, efficacy, and safety of levetiracetam in this patient population.